Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 2/20 | 0.37 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.37 |
| ▸ | GRIA4 | P48058 | 2/20 | 0.37 |
| ▸ | GRIK3 | Q13003 | 2/20 | 0.37 |
| ▸ | GRIK5 | Q16478 | 2/20 | 0.37 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.37 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7103458 | 1.00 | GRIK1 (0.37) | GRIK1GRIA2GRIA4GRIK3GRIK5 | |
| SCHEMBL4681859 | 0.78 | GRIK1 (0.46) | GRIK1GRIA2GRIA4GRIK3GRIK5 | |
| SCHEMBL1323858 | 0.78 | GRIK1 (0.41) | GRIK1GRIA2GRIA4GRIK3GRIK5 | |
| SCHEMBL7099830 | 0.78 | MAPT (0.31) | — | |
| SCHEMBL7099832 | 0.78 | MAPT (0.31) | — | |
| SCHEMBL7103467 | 0.77 | TSHR (0.38) | TSHRTRPA1 | |
| SCHEMBL7103464 | 0.77 | TSHR (0.38) | TSHRTRPA1 | |
| SCHEMBL7105181 | 0.75 | NPSR1 (0.44) | TRPA1 | |
| SCHEMBL7105178 | 0.75 | NPSR1 (0.44) | TRPA1 | |
| SCHEMBL7107474 | 0.74 | CA1 (0.30) | CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1000939-B1 | Producing z-isomer of hydrogen bromide salt of 2-aminothiazole derivative | SUMITOMO CHEMICAL CO (JP) | 2003-09-17 | — | — | EP | disclosed |
| US-6403572-B1 | REACTING ACID SALT OF A 2-AMINOTHIAZOLE COMPOUND WITH INORGANIC ACID | SUMITOMO CHEMICAL CO., LTD. (JP) | 2002-06-11 | — | — | US | disclosed |
| US-20020058818-A1 | Producing Z-isomer of hydrogen bromide salt of 2-aminothiazole derivative | SUMITOMO CHEMICAL CO., LTD. | 2002-05-16 | — | — | US | disclosed |
| US-6340763-B1 | SALT FORMATION AND CRYSTALLIZATION, REACTION OF HALOGENATED COMPOUND AND THIOUREA COMPOUND | SUMITOMO CHEMICAL CO., LTD. (JP) | 2002-01-22 | — | — | US | disclosed |
| EP-1000939-A1 | Producing z-isomer of hydrogen bromide salt of 2-aminothiazole derivative | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2000-05-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020058818-A1 | Producing Z-isomer of hydrogen bromide salt of 2-aminothiazole derivative | ZYX, H1-0, HAO2 | GRIK1 272/4885GRIA2 476/4885GRIA4 1174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.